AusperBio Appoints Wen Xuetao as Chief Commercial Officer to Accelerate China Market Strategy

Nov 12, 2024 08:42 CST Updated 08:42

AusperBio

Biological Vaccine and Nucleic Acid Drug Developer

Breaking News

On November 11, 2024, AusperBio (Ausper Biopharma Co., Ltd. and AusperBio Therapeutics Inc.) announced:Appointment of Mr. Xue Tao Wen as Chief Commercial Officer (CCO) of AusperBio.He will be fully responsible for AusperBio's commercialization layout, operations, and business development in the Chinese market.

Mr. Xue Tao Wen has over 20 years of profound experience in the healthcare industry, having held key positions such as Regional Manager, Senior Sales Director, and Vice President at Pfizer, Bayer, Gilead Sciences, Zelgen, and Everest Medicines. By driving scientific and commercial innovation, he has demonstrated exceptional strength in product commercialization, making a significant impact on the treatment of various major diseases and helping multiple biopharmaceutical companies achieve annual sales exceeding 1 billion for individual products. During his tenure at Gilead Sciences China, Mr. Wen implemented innovative commercialization models that benefited a large population of hepatitis B and hepatitis C patients in China. He promoted the implementation of a series of "Eliminate Hepatitis C" projects across China and grassroots markets, helping hepatitis C patients achieve a cure and offering a better future for those with hepatitis B.

Dr. Guofeng Cheng, co-founder and CEO of AusperBio, said:"We are very pleased to welcome Xue Tao to the team. His joining marks a new phase of development for AusperBio. We have previously worked together at Gilead, and it is an honor to have him join AusperBio today in our entrepreneurial journey to realize the vision of eliminating hepatitis B worldwide. In addition to his successful experience in commercializing cross-disciplinary new products, Xue Tao has also been responsible for production and quality control, as well as leading cross-functional teams. His contributions will significantly empower the establishment of AusperBio’s core values and the realization of our strategic goal to integrate R&D and commercialization."

Mr. Wen Xuetao stated:"I am thrilled to join AusperBio at this pivotal moment of rapid growth. AusperBio stands out among numerous innovative drug development companies with its world-class scientific team, internationally leading new drug R&D platform, and an incredible clinical development strategy and efficiency that peers find hard to match. I look forward to collaborating with the team to build an innovative system for disease prevention, treatment, and management, providing patients with higher-quality medical solutions and addressing many unmet clinical needs."

About AusperBio

AusperBio is a clinical-stage innovative drug development company operating simultaneously in China and the United States. It is committed to developing First-in-class and Best-in-class proprietary innovative targeted delivery small nucleic acid drugs. AusperBio owns the proprietary Med-Oligo™ ASO patent technology platform, focusing on functional cures for chronic hepatitis B (HBV) and highly efficient targeted treatments for liver diseases, while expanding into targeted small nucleic acid therapies for new targets beyond the liver. AusperBio’s strategy is to combine its world-leading Med-Oligo™ oligonucleotide technology with specific and highly efficient targeting technologies to address a wide range of currently unmet medical needs.

E.N.D

Previous article recommendations:

Total investment of approximately 3 billion yuan, with a construction area of 100,000 square meters, a cell therapy drug research and development and production base in China has officially started construction.

The World's First In Vivo CAR Gene Therapy Approved for Phase I Clinical Trial Completes First Patient Dosing

Another Gene Therapy Drug Approved for Marketing

A Gene Therapy Company in China Completes 150 Million Yuan Series A Financing

The World's First TIL Cell Therapy Generates $640 Million in Half a Year, Expected to Exceed $1.1 Billion for the Full Year

The World's First Stem Cell Therapy for Type 1 Diabetes Advances to Phase 3 Clinical Trials

Purchase Price Approximately 187 Million Yuan: Northeast Pharmaceutical to Officially Acquire 70% Equity of a Cell Therapy Company in China

Official Announcement! Stem Cell Exosomes Not Managed as Medical Devices

World's First! Bionbase's Non-Viral Targeted Integration PD1-CAR-T Therapy for Lupus Erythematosus Approved for Clinical Trials in China

YaoTang Biotech Develops Novel LNP Delivery System for Precise Editing of Bone Marrow Cells

Focusing on CGT and other cell industries, a cell technology company in China officially opens.

Shanghai Releases Three-Year Action Plan, Continuously Supporting Innovation and R&D in Frontier Areas Such as Cell and Gene Therapy, Nucleic Acid Drugs, and Brain-Computer Interfaces (with Policy Interpretation)

Guangzhou Issues New Policy to Accelerate the Industrialization of Antibody Drugs, Vaccines, Cell and Gene Therapies, Recombinant Proteins, and Peptides

FDA Approves Mesenchymal Stromal Cell (Non-Stem Cell) Drug for Clinical Trials

Major Release: The World's First International Standard for Stem Cell Data Management is Here

CDE Releases Common Issues and Technical Requirements for Lentivirus Testing in the Cell and Gene Therapy Field

World’s First Circular RNA Drug Receives FDA Approval for Clinical Trials

West Lake Bio Achieves Breakthrough Progress in World's First Red Blood Cell Immunotherapy

Saiyun Bio Completes Tens of Millions of Yuan in Angel Financing, Aiding Development of Novel Drug Delivery Vectors

AstraZeneca Insurance Fraud Case Impacts Executives of Multiple Listed Companies

CSPC's First mRNA-LNP-Based CAR-T Cell Therapy (SYS6020) Receives New Indication Clinical Trial Approval

About 1/6 of China's cell and gene therapy drug clinical trial projects are located in Zhangjiang, with a "gushing" of innovative achievements.

China's AAV Gene Therapy on the Verge of Explosion, 44 INDs Approved, 4 Entered Phase III Clinical Trials

GenScript Biotech Announces Termination of Merger with Legend Biotech, Adjusted to Equity Method Investment

Chengdu Multi-Department Jointly Releases Notice on Pilot Implementation in Advanced Medical Fields such as Cell Therapy and Gene Therapy in Regenerative Medicine

Disclaimer: The content is sourced from the official company.This article is intended for knowledge sharing. All content is for reference only and does not constitute any advice.